Recursion Pharmaceuticals and Exscientia announce merger to transform drug development
Recursion Pharmaceuticals Inc. (Nasdaq: RXRX) and Exscientia plc (Nasdaq: EXAI) have announced a landmark merger, combining their strengths to form a formidable entity in drug discovery and development. This strategic union is set to enhance their technological capabilities and expand their clinical pipeline, paving the way for more effective and affordable medicines. Key Details of […]